Johnson & Johnson
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson VELCADE [reported separately through FY2020Q4] by Quarter
VELCADE (bortezomib) [reported separately through FY2020Q4] — Worldwide sales ($M) ($M)
Johnson & Johnson VELCADE [reported separately through FY2020Q4]: $97M in Q4 2020, down 15.7% from a year earlier. That is the lowest of the 17 quarters on record here. No newer figure appears in the documents we track.
Where the Q4 2020 figure comes from
Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)
Source: Form 10-K (filed 2021-02-22) ↗
Reported in Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | VELCADE (bortezomib) [reported separately through FY2020Q4] — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2020 | Jan 3, 2021 | 97 | -15.7% | Form 10-K (filed 2021-02-22) ↗ |
| Q3 2020 | Sep 27, 2020 | 105 | -29.5% | Form 10-Q (filed 2020-10-23) ↗ |
| Q2 2020 | Jun 28, 2020 | 98 | -56.2% | Form 10-Q (filed 2020-07-24) ↗ |
| Q1 2020 | Mar 29, 2020 | 108 | -58.9% | Form 10-Q (filed 2020-04-29) ↗ |
| Q4 2019 | Dec 29, 2019 | 115 | -54.4% | Form 10-K (filed 2021-02-22) ↗ |
| Q3 2019 | Sep 29, 2019 | 149 | -45.0% | Form 10-Q (filed 2020-10-23) ↗ |
| Q2 2019 | Jun 30, 2019 | 224 | -20.0% | Form 10-Q (filed 2020-07-24) ↗ |
| Q1 2019 | Mar 31, 2019 | 263 | -16.0% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2018 | Dec 30, 2018 | 252 | -7.0% | Form 10-K (filed 2021-02-22) ↗ |
| Q3 2018 | Sep 30, 2018 | 271 | -0.7% | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2018 | Jul 1, 2018 | 280 | -3.4% | Form 10-Q (filed 2018-08-02) ↗ |
| Q1 2018 | Apr 1, 2018 | 313 | +11.8% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2017 | Dec 31, 2017 | 271 | -1.1% | Form 10-K (filed 2019-02-20) ↗ |
| Q3 2017 | Oct 1, 2017 | 273 | – | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2017 | Jul 2, 2017 | 290 | – | Form 10-Q (filed 2018-08-02) ↗ |
| Q1 2017 | Apr 2, 2017 | 280 | – | Form 10-Q (filed 2018-05-01) ↗ |
| Q4 2016 | Jan 1, 2017 | 274 | – | Form 8-K (a8k2017q4exhibit9915.htm, filed 2018-01-23) ↗ |
Breakdown
What makes up VELCADE [reported separately through FY2020Q4]
- VELCADE (bortezomib) [reported separately through FY2020Q4] — U.S. sales ($M)0 · Q4 2020
- VELCADE (bortezomib) [reported separately through FY2020Q4] — International sales ($M)97 · Q4 2020
- VELCADE (bortezomib) [reported separately through FY2020Q4] — Worldwide reported growth YoY (%)-15.2% · Q4 2020
- VELCADE (bortezomib) [reported separately through FY2020Q4] — Worldwide operational (constant-currency) growth YoY (%)-18.5% · Q4 2020
Cite this data
StockData. (2026). Johnson & Johnson VELCADE [reported separately through FY2020Q4] ($M), quarterly Q4 2016–Q4 2020 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-velcade
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.